Partners

Vectalys provides viral vector production and cell transduction activities for pharmaceutical industry, biotech companies and academic laboratories.

Vectalys, coordinator of the SHIP-In project to develop new and innovative cellular systems for the biopharmaceutical industry.

The SHIP-In project consists in optimizing this new technology to cater for the demands of the biopharmaceutical industry. The aim is to provide pharmaceutical and cosmetics companies with an unlimited supply of human cells which meet quality criteria that are not available today. Eventually, SHIP-In should facilitate the discovery of new molecules and generally speed up the therapeutic innovation process. The project has received the label of the Alsace BioValley cluster in Alsace, France, in November 2008 and is co-sponsored by France’s Cancer Bio Santé and Medicen research poles.

The project has started in April 2009 and is due to run for 36 months with a total project funding of €4.4 million.

More details on the project in the press release: English version or French version

Feder_Logo

Vectalys take parts in LIV-ES, a European collaborative research project on the development of culture conditions for the differentiation of hES cells into hepatocytes.

LIV-ES’ goal is to develop innovative conditions and standardized protocols to provide a renewable source of human hepatocytes (liver cells) for the treatment of liver diseases. The final goal is to deliver a bank of fully-mature human hepatocytes derived from hES cell lines developed by LIV-ES partners.

The consortium brings together 9 internationally renowned research teams from France, United Kingdom, Spain, Finland and Israel.

More information on the LIV-ES website

PF7

| Legal notice Site map